AVAVA Secures $45 Million Financing Led by Catalio Capital Management

AVAVA, a Waltham, Massachusetts-based medical aesthetics company, has secured $45 million in new financing led by Catalio Capital Management, split between $30 million in equity and a $15 million debt facility. The capital is earmarked for continued commercial expansion, further development of the company's innovation pipeline, and international growth.

AVAVA was founded in 2017 out of Blossom Innovations, a Boston-based incubator connected to the research laboratories of Dr. Rox Anderson and Dr. Dieter Manstein, both serial scientist-entrepreneurs with a long track record of commercially successful innovations in aesthetic dermatology over the past two decades. The company's flagship product, Miria, is an FDA-approved high-energy laser device built around AVAVA's proprietary Focal Point Technology, which concentrates energy in precisely targeted tissue regions while limiting exposure to surrounding skin. Miria is marketed as the first high-energy device of its kind effective across all skin tones, addressing a longstanding gap in laser-based dermatology devices that have historically performed unevenly on darker skin.

This financing follows an earlier $35 million round the company raised in 2024 to support the initial commercial rollout of Miria, and Catalio Capital, a healthcare-focused investment firm, has now backed the company across at least two rounds. The mixed equity-debt structure of this latest raise, $30 million in equity against $15 million in debt, is a structure increasingly common among growth-stage medical device companies with an approved, revenue-generating product already in market, allowing founders to fund expansion while limiting additional equity dilution relative to a straight equity round of the same size.

For founders in medical device and healthtech, AVAVA's path, a university-lab-incubated device company reaching FDA approval and then layering debt into later financing rounds once commercial traction is established, is a useful template for how capital structure can evolve once a product moves from approval to scale. The skin-tone performance gap AVAVA is targeting has been a long-documented limitation of laser-based dermatology devices, many of which rely on light-absorption principles that work less reliably on darker skin, and closing that gap represents both a clinical need and a meaningfully underserved commercial segment within the broader medical aesthetics market. Investors backing a second round into the same device company suggest early commercial signals from Miria's rollout since 2024 have been strong enough to justify scaling rather than pivoting.

Founders building in healthtech or medical devices can find active investors through the match tool, browse healthtech investors in the directory, or check the live listing of current opportunities. Catch up on more coverage in the newsroom, or register on AngelLinx to start a raise.

AngelLinx Intelligence | angellinx.ai